Piccardi-Lassueur-Little Syndrome

Piccardi-Lassuet-Little syndrome (PLLS) is a rare dermatological disease characterized by the appearance of patchy areas of depigmentation on the skin, often followed by the development of melanocytic carcinoma.

Piccardi–Lassuet syndrome was first described in 1902 by Italian dermatologist Gabriel Piccardi, who described 12 cases of the disease. However, it was not until 2003 that this syndrome was renamed Piccardi–Lassuet–Little, as Little's scientist in England also described the disease.

Piccardi syndrome is characterized by the appearance of depigmentation spots of various sizes and shapes on the skin. They can be round, oval or irregular in shape. The spots are usually brown or black in color, but can also be white or gray.

One of the most characteristic signs of PLLS is the development of melanocytic tumors in areas of skin with depigmentation. This could be melanoma, basal cell carcinoma, or another type of skin cancer.

Treatment for PLLS involves removal of areas of depigmentation and subsequent monitoring of the skin. If melanocytic cancer develops, appropriate treatment is necessary.

Piccardi–Lassure–Little syndrome is a rare skin disease that manifests itself as a disorder of pigmentation and skin texture in the area of ​​the nose, forehead and eyebrows. It was first described by French dermatologist Louis Gonzaluis Piccari (1912-2004), Italian dermatologist Andrea Lassueur (1898-1972) and American dermatologist Horace Little (1877-1814).

The symptom is a type of melasma caused by a disruption in the regulation of melanin synthesis due to impaired expression of tyrosine kinase receptors in the melanocyte microenvironment. Cases of the syndrome have also been described during pregnancy, obesity, and taking antidepressants.

The syndrome has certain characteristics, among which the most noticeable is a disorder of pigmentation of the skin near the eyes and lips. Pink or pink spots appear on the skin, as well as follicular hyperkeratosis, it